The psoriasis drugs market refers to the market for drugs used to treat psoriasis, a chronic skin condition characterized by red, scaly patches on the skin. Psoriasis affects approximately 125 million people worldwide and can be a debilitating and painful condition, affecting a patient’s quality of life.
There are several types of drugs used to treat psoriasis, including topicals, systemic therapies, and biologic treatments. Topicals, such as creams and ointments, are applied directly to the skin and are typically the first line of treatment for mild psoriasis. Systemic therapies, such as oral medications and injections, are used for moderate to severe psoriasis, and biologic treatments, such as monoclonal antibodies, are used for patients who have not responded to other treatments.
Request For Free Sample Report of “Psoriasis Drugs Market”@ https://www.persistencemarketresearch.com/samples/25102
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 – 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to expand at a CAGR of nearly 6.5% over the next ten years.
An array of agents exist for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis typically receive topical treatments that modulate gene transcription, promote keratinocyte differentiation, and inhibit cell proliferation.
A number of innovative and advanced therapies for the treatment and management of psoriasis are under development, many of which have novel targets and mechanisms of action. Psoriasis is linked with a number of medical conditions inclusive of psoriatic arthritis, depression, and cardio metabolic syndrome. The most commonly occurring form of psoriasis is chronic plaque.
Key Takeaways from Market Study
- Topical products are expected to continue holding over one-third market value share through 2031, primarily because of clinically approved topical ointments, foams, and creams available for the management of inflammation and rash due to psoriasis.
- Efficiency of corticosteroids for skin irritability and inflammation makes corticosteroid the leading segment with over 34% of revenue share in 2021.
- Easy availability of psoriasis drugs in hospital pharmacies and large distribution networks of hospital chains make it the largest segment, with more than 39% market share.
- Plaque psoriasis is the most commonly occurring autoimmune disease, accounting for a revenue share of around 85% in 2021.
- Presence of a large number of manufacturers, rising public awareness, and easy availability of psoriasis drugs and treatment options make North America the leading regional market with over 27% market share in 2021.
“Growing adoption of combination therapy and favourable reimbursement support for psoriasis to drive market growth,” says an analyst of Persistence Market Research.
Buy Full Report Now @ https://www.persistencemarketresearch.com/checkout/25102
Market Competition
Companies such as Amgen and Sun Pharma have been strongly working toward the development of an extensive clinical pipeline and manufacturing of new product lines for the treatment of psoriasis.
- In December 2021, Amgen announced positive top-line results from the Otezla® (apremilast) Phase 3 DISCREET study in moderate to severe genital psoriasis.
- In September 2020, Sun Pharma announced the launch of ILUMYA® (tildrakizumab) for the treatment of plaque psoriasis, in Japan.
Similarly, other psoriasis drug manufacturers are also trying to maintain and strengthen their portfolios through collaborations with local players or distribution partners. All such recent developments related to companies manufacturing psoriasis drugs have been tracked by the team at Persistence Market Research, which are available in the full report.
Key companies operating in the psoriasis drugs market include Janssen Biotech Inc, Novartis International Ltd., Amgen Inc, Pfizer Inc., Takeda Pharmaceutical Company Ltd. Merck & Co, Inc., Abb Vie Inc., Eli Lilly and Company, Boehringer Ingelheim GmbH, and Sun Pharmaceutical Industries Ltd.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the psoriasis drugs market in its latest study, presenting historical demand assessment of 2016 – 2021 and projections for 2022 – 2031.
The research study is based on the product (topical, oral, and injectable), drug class (interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitor), distribution channel (hospital pharmacies, retail pharmacies, and e-Commerce), and indication (guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and plaque psoriasis), across seven key regions of the world.
Request Customization @ https://www.persistencemarketresearch.com/request-customization/25102
Key Questions Answered in This Report.
- What are the Roadblocks for Psoriasis Drugs Market Suppliers?
- What are the Key Opportunities for Psoriasis Drugs Market Manufacturers?
- How is Focus on Safety Influencing Psoriasis Drugs Market Demand?
- What is the Regulatory Impact on Global Sales of Psoriasis Drugs Market?
- Which Region Offers the Largest Opportunity for Sales of Psoriasis Drugs Market?
- Where Does the U.S. Stand in the Market for Psoriasis Drugs Market?
- What Is the Outlook for Psoriasis Drugs Market Manufacturers in China?
- Why is Germany a Lucrative Market for Psoriasis Drugs Market Manufacturers?
- Why Will Belgium Outpace Other European Markets for Psoriasis Drugs Market?
- Why is There High Demand for Tires in Psoriasis Drugs Market?
- Why are Sales of Psoriasis Drugs Market Surging?
For More Premium Insights, Check out the Link:
DNA and RNA Sample Preparation market
Single-Use Bioprocess Systems market
Macular Degeneration Treatment market
About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research
Japan
Persistence Market Research
1-2-1 Kinshi Arca Central Building 14/F Tokyo, 130-0013 Japan
Call 0800-222-1088
United States
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com